Drugs / aTIV-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03314662 | Oct → Dec 2017 | influenza | Seqirus | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aTIV-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03314662 ↗ |
| Known as | Fluad | “a licensed adjuvanted trivalent influenza vaccine (aTIV-1; Fluad™)” PMID 31635976 ↗ Oct 2019 |
| Modality | Vaccine | “licensed adjuvanted trivalent influenza vaccine” PMID 31635976 ↗ Oct 2019 |